A FormBlends network publication
FormBlends Video Library

Videos

27 pages in this section, most recently updated September 4, 2026.

  1. 01

    Fact-check: an emergency physician's top five GLP-1 problems

    Nick Sterling, MD, PhD ranks what he sees in the emergency department: nausea and vomiting, dehydration and kidney injury, starvation ketosis, muscle loss and low mood. Useful clinical texture; not incidence data, and two sections lean on general evidence rather than GLP-1 trials.

    Updated September 4, 2026

  2. 02

    Fact-check: Mayo Clinic Proceedings on tirzepatide in type 1 diabetes

    Two Mayo research fellows summarise their retrospective study of tirzepatide in adults with type 1 diabetes and obesity. The numbers match the paper; the use is off-label and the study design limits what it can show.

    Updated September 4, 2026

  3. 03

    Fact-check: NEJM's two-minute summary of the SELECT trial

    The journal's own video abstract of semaglutide and cardiovascular outcomes in obesity. Every figure is from the paper; we add the ones a two-minute cut leaves out: hazard ratio, absolute difference, dropouts and what the trial does not show.

    Updated September 4, 2026

  4. 04

    Fact-check: Ohio State's 90-second answer to what a GLP-1 agonist is

    A hospital explainer that gets the mechanism right in under two minutes. What it compresses, what it cannot fit, and the label and trial sources behind each sentence.

    Updated September 4, 2026

  5. 05

    Fact-check: the Veterans Health Administration's subcutaneous injection demonstration

    A government health system's step-by-step vial-and-syringe technique. Correct throughout for what it shows; here is what a person injecting a GLP-1 from a vial must add, especially about concentration and units.

    Updated September 4, 2026

  6. 06

    Fact-check: Yale Medicine on how obesity medicine works

    A Yale physician explains the defended fat-mass set point and why medications and surgery succeed where lifestyle alone often cannot hold. A sound framework, presented without numbers; here are the numbers and the caveats.

    Updated September 4, 2026

  7. 07

    Fact-check: Cleveland Clinic's one-minute SELECT result

    A SELECT investigator gives the headline in 61 seconds: about 20 percent fewer cardiovascular events. Right, but relative; here are the absolute numbers, and a caption error to ignore.

    Updated September 4, 2026

  8. 08

    Fact-check: Dr. Spencer Nadolsky on the top five GLP-1 side effects and what to do

    An obesity medicine physician on nausea, constipation, reflux, diarrhoea and fatigue: the time course, the food changes that help, and when his clinic adds medication. Matches the trial pattern; the medication steps need your own prescriber.

    Updated September 4, 2026

  9. 09

    Fact-check: Endocrine Society journal club on tirzepatide's metabolic effects

    Three endocrinologists dissect a JCEM metabolomics paper on tirzepatide. Rigorous and appropriately sceptical; we explain what the paper is, what it is not, and why it matters little to a patient deciding on treatment.

    Updated September 4, 2026

  10. 10

    Fact-check: Harvard's teaching video on GLP-1 agonists for weight loss

    A Brigham and Women's endocrinologist gives the SCALE, STEP 1, STEP 8 and STEP 4 numbers in six minutes. We checked every figure against the papers and list what has changed since 2022.

    Updated September 4, 2026

  11. 11

    Fact-check: Weber State University's insulin syringe demonstration

    A nursing skills video on drawing up and injecting insulin subcutaneously. The syringe handling transfers to any vial; the insulin-mixing section does not apply to GLP-1s and the 45-degree angle differs from pen labels.

    Updated September 4, 2026

  12. 12

    Fact-check: Yale Medicine on medical therapies for weight management

    Yale clinicians on incretin drugs as one part of a program, the wide variation in individual response, and combining medication with endoscopic procedures. Accurate and general; the response-variability point deserves the trial figures behind it.

    Updated September 4, 2026

  13. 13

    Fact-check: Harvard's teaching video on prescribing GLP-1 agonists for weight loss

    Indications, contraindications, cautions, injection sites, pen differences and titration for liraglutide and semaglutide, checked line by line against the Saxenda and Wegovy labels. What has changed since 2022.

    Updated September 4, 2026

  14. 14

    Fact-check: Speed Pharmacology's incretin segment in Drugs for Diabetes

    A 2017 pharmacology lecture covers every diabetes drug class in 17 minutes. The incretin section is accurate and still a good primer; here is what a 2026 viewer needs to add.

    Updated September 4, 2026

  15. 15

    Fact-check: the American Pharmacists Association's subcutaneous administration clip

    A pharmacist-training video on subcutaneous injection into the back of the upper arm, filmed for vaccines. What carries over to a GLP-1 self-injection and what does not.

    Updated September 4, 2026

  16. 16

    Fact-check: the Anesthesia Patient Safety Foundation on GLP-1s before anaesthesia

    Case reports of a full stomach despite fasting, the June 2023 ASA guidance to hold weekly agents for a week, and gastric ultrasound as a bedside check. Accurate for its date; a 2024 multi-society statement has since changed the default advice.

    Updated September 4, 2026

  17. 17

    Fact-check: two trialists interpret the tirzepatide data (CMHC)

    Dr. Anne Peters and Dr. Juan Frias discuss tirzepatide as of early 2023: trial results, dose escalation, switching from a GLP-1, the contraceptive caution and cardiovascular data. What has changed since, and what was the speaker's practice rather than the label.

    Updated September 4, 2026

  18. 18

    Fact-check: Yale Medicine on lifestyle interventions for weight management

    Yale's weight management team on what diet, exercise, sleep and mood do and do not achieve. The 3 to 4 percent figure is at the low end of the trial literature; here is the range and why it varies.

    Updated September 4, 2026

  19. 19

    Fact-check: Cleveland Clinic's 45-minute GLP-1 question and answer

    An endocrinologist answers the questions patients ask most: how the drugs work, how long to take them, how much weight to expect, how common the side effects are, and what is rare but real. Sound throughout; a few figures are rounded and one analogy oversells the stomach.

    Updated September 4, 2026

  20. 20

    Fact-check: Johns Hopkins Medicine's podcast on how GLP-1s work and who they help

    A 38-minute conversation with an obesity medicine physician at Johns Hopkins. Strong on body composition and long-term framing; we add the trial numbers and check the compounding section against the FDA's current position.

    Updated September 4, 2026

  21. 21

    Fact-check: Mayo Clinic Minute on weaning off weight-loss medications

    A one-minute news piece on stopping: high chance of regain if you stop early, appetite signals return, talk to a clinician first. Right in outline; here are the withdrawal trials that put numbers on it.

    Updated September 4, 2026

  22. 22

    Fact-check: Stanford Health Care's hour on GLP-1 receptor agonists, the truth behind the trend

    A clinical pharmacist walks through physiology, every agent, the A1c and weight trials and the outcome trials. Thorough and mostly right; several trial sizes and dates are quoted loosely and one head-to-head figure is wrong by two orders of magnitude.

    Updated September 4, 2026

  23. 23

    Fact-check: TCOYD's Mounjaro versus Ozempic showdown

    Two endocrinologists from the nonprofit Taking Control Of Your Diabetes score tirzepatide against semaglutide in eight categories. The trial reasoning is sound; two pieces of practical advice are personal opinion that we do not endorse.

    Updated September 4, 2026

  24. 24

    Fact-check: the Endocrine Society podcast on compounded obesity medications

    An NYU endocrinologist explains compounding, the shortage rules, why compounded GLP-1s are not FDA approved and the dosing confusion they cause. Largely accurate and sponsored by Eli Lilly; the quantitative claims are unnamed on air and we could only partly trace them.

    Updated September 4, 2026

  25. 25

    Fact-check: Stanford Health Care's dietitian webinar on managing GI side effects

    An hour on nausea, vomiting, constipation and diarrhoea with the trial percentages by week and the food strategies that help. The numbers trace to a published review; here is where they come from and what a tirzepatide user should add.

    Updated September 4, 2026

  26. 26

    Fact-check: Stanford Medicine's three minutes on what the science says about GLP-1s

    Several Stanford faculty on benefits, side effects and weight bias in a short news-style piece. Mostly right; one cardiovascular figure is broader than the trial it seems to rest on.

    Updated September 4, 2026

  27. 27

    Fact-check: UCSF grand rounds on anti-obesity medications, beyond the scale

    The director of UCSF's weight management clinic on treatment goals by percentage lost, every approved medication with its one- and two-year numbers, GLP-1 pharmacology, side-effect rates and the sex difference in tirzepatide response. Dense and well sourced; a few percentages need their denominators.

    Updated September 4, 2026